-
Elanco announces the underwriters of its recent initial public
offering have exercised in full their over-allotment option purchase
an additional 9.435 million shares
-
Elanco sets third quarter earnings call for Nov. 6, its first as an
independent company
-
Elanco to ring the New York Stock Exchange Opening Bell® in
celebration of its recent listing
GREENFIELD, Ind.--(BUSINESS WIRE)--
Elanco Animal Health Incorporated (NYSE:ELAN) announced the underwriters
of its initial public offering (IPO) have fully exercised their option
to purchase an additional 9.435 million shares at the initial public
offering price of $24.00 per share, less underwriting discounts,
bringing the total IPO size to 72.335 million shares.
Elanco’s shares began trading on the New York Stock Exchange (NYSE) on
Sept. 20 under the ticker symbol “ELAN.” In celebration, Elanco is
scheduled to ring the Opening Bell at NYSE today, Monday, Sept. 24.
“This marks an exciting new chapter for Elanco as we start our journey
as an independently operated, publicly traded company,” said Jeff
Simmons, president and chief executive officer of Elanco.
In addition, Elanco announced it will report its financial results for
the third quarter of 2018 on Tuesday, Nov. 6, 2018. This marks Elanco’s
first financial report as an independent company. Elanco will also
conduct a conference call on that day with the investment community and
media to further detail the company's financial performance.
The conference call will begin at 8 a.m. eastern time. Investors, media
and the general public can access a live webcast of the conference call
through a link that will be posted on Elanco's website at https://investor.elanco.com
. A replay will also be available on the website following the
conference call.
The NYSE will live stream the Opening Bell ceremony on it’s website at https://livestream.com/NYSE,
beginning at 9:26 am Eastern Time on Monday, Sept. 24. A video of the
bell ringing will also be archived on the same page.
A registration statement relating to these securities was filed with,
and declared effective by, the U.S. Securities and Exchange Commission
(SEC). This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Elanco Animal Health
Founded in 1954, Elanco provides comprehensive products and knowledge
services to improve animal health and food-animal production in more
than 90 countries around the world. We value innovation, both in
scientific research and daily operations, and strive to cultivate a
collaborative work environment for more than 5,800 employees worldwide.
Together with our customers, we are committed to raising awareness about
global food security, and celebrating and supporting the human-animal
bond. Our worldwide headquarters and research facilities are located in
Greenfield, Indiana.
This press release contains forward-looking statements that are based on
management's current expectations, but actual results may differ
materially due to various factors. These statements relate to the
offering. There are significant risks and uncertainties relating to the
offering. Important factors that could cause actual results to differ
materially from management’s expectations include, without limitation:
the satisfaction of customary closing conditions relating to the IPO;
capital market risks; and the impact of general economic or industry
conditions. There can be no guarantees that Elanco will achieve the
anticipated benefits of the IPO. Elanco’s ability to achieve the
anticipated benefits of the IPO may be materially affected by such
factors as changes to the business, results of operation or financial
condition of Elanco, changes in the animal health or pharmaceutical
industries, adverse market or macroeconomic conditions and other factors
outside Elanco's control. For additional information about the factors
that affect Elanco's business, please see its filings with the SEC.
Elanco undertakes no duty to update forward-looking statements, except
as may be required by law.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20180924005458/en/
Elanco Animal Health Incorporated
Media:
Colleen Parr Dekker,
317-989-7011
colleen_parr_dekker@elanco.com
or
Investors:
Jim
Greffet, 317-383-9935
greffet_james_f@elanco.com
Source: Elanco Animal Health Incorporated